“Biosimilars Would Have Reimbursement Parity With Innovators Under Health Reform Bill” (The Pink Sheet)
The potential for physicians to favor innovator biologics over follow-on biologics because of a reimbursement advantage would be eliminated under an amendment to health care reform legislation adopted by the Senate Finance Committee Sept. 23.
This is copyright protected information, to receive the full article, please click here to sign up and register.
“Frances D. Fergusson And John P. Mascotte Elected To Pfizer’s Board Of Directors” (Stockpoint)
“Pfizer and Eisai settle dispute over Aricept rights; Lyrica deal” (PharmaTimes)
“NiCox celebrates submission of NDA for naproxcinod” (PharmaTimes)
“Biofrontera AG (DE) – Ad hoc: Biofrontera AG successfully completes capital increase” (PharmaLive)
“Swine flu vaccinations will soon be on their way” (USA Today)
“Lack of sleep may play role in Alzheimer’s” (Reuters)
SUBSCRIBE